RT Journal Article
SR Electronic
T1 Statistical analysis for the development of a Deep Learning model for classification of images with TDP-43 pathology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.12.24300689
DO 10.1101/2024.02.12.24300689
A1 Muñoz, Azucena
A1 Oliveira, Vasco
A1 Vallejo, Marta
YR 2024
UL http://medrxiv.org/content/early/2024/02/14/2024.02.12.24300689.abstract
AB Diagnosing Amyotrophic Lateral Sclerosis (ALS) remains a hand challenge due to its inherent heterogeneity. Notably, the occurrence of TDP-43 cytoplasmic aggregation in approximately 95% of ALS cases has emerged as a potential indicative hallmark. In order to develop deep learning models capable of distinguishing TDP-43 proteinopathic samples from their healthy counterparts, a comprehensive understanding of the sample set becomes imperative, particularly when the sample size is limited. The samples in question encompassed images obtained via an immunofluorescence procedure, employing super high-resolution microscopy coupled with meticulous processing. A feature-extracted dataset was created to collect meaningful features from every sample to approach three different classification problems (TDP-43 Pathology, TDP-43 Pathology Grades and ALS) based on the number of red and pink pixels, signifying cytoplasmic and nuclear TDP-43 presence. A series of diverse statistical approaches were undertaken. However, definitive outcomes remained elusive, although it was suggested that a classification based on the presence of TDP-43 proteinopathy was better than the one based on the presence of ALS for training the model.The dataset was reduced by eliminating the problematic samples through curation. Analyses were repeated using t-student tests and ANOVA, and visualisation of patient inter-variability was performed using hierarchical clustering. The TDP-43 pathology classification results showed significant differences in the number of red and pink pixels, the total amount of protein and the cytoplasmic and nuclear proportions between healthy and pathological samples between groups. These findings suggested that images classified according to the presence of TDP-43 proteinopathy are more suitable for training deep learning models.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of post-mortem tissue received ethical clearance from the East of Scotland Research Ethics Service (reference number 16/ES/0084), complying with the Human Tissue (Scotland) Act of 2006. Ethical approval for utilising these postmortem tissues in research was granted by the ethics committee of the Edinburgh Brain Bank and the Academic and Clinical Central Office for Research and Development (ACCORD) medical research ethics committee (AMREC). Clinical data associated with these tissues were sourced from the Scottish Motor Neurone Disease Register (SMNDR) and the Care Audit Research and Evaluation for Motor Neurone Disease (CARE-MND) platform, with ethical endorsement from the Scotland A Research Ethics Committee (references 10/MRE00/78 and 15/SS/0216).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.